Cargando…
Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
Objective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid”, “thiocti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272801/ https://www.ncbi.nlm.nih.gov/pubmed/22331979 http://dx.doi.org/10.1155/2012/456279 |
_version_ | 1782222839508631552 |
---|---|
author | Mijnhout, Gerritje S. Kollen, Boudewijn J. Alkhalaf, Alaa Kleefstra, Nanno Bilo, Henk J. G. |
author_facet | Mijnhout, Gerritje S. Kollen, Boudewijn J. Alkhalaf, Alaa Kleefstra, Nanno Bilo, Henk J. G. |
author_sort | Mijnhout, Gerritje S. |
collection | PubMed |
description | Objective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid”, “thioctic acid”, “diabet(∗)”, and the MeSH-terms “thioctic acid” and “diabetes mellitus”. Randomised controlled trials using the TSS score as the outcome measure were selected and assessed for their methodological quality. Study selection and quality assessment were performed independently by three observers. Results. Overall, the pooled standardized mean difference estimated from all trials revealed a reduction in TSS scores of −2.26 (CI: −3.12 to −1.41; P = 0.00001) in favour of alpha lipoic acid administration. Subgroup analyses of oral administration (−1.78 CI: −2.45 to −1.10; P = 0.00001) and intravenous administration (−2.81 CI: −4.16 to −1.46; P = 0.0001) confirmed the robustness of the overall result. Conclusions. When given intravenously at a dosage of 600 mg/day over a period of 3 weeks, alpha lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain (grade of recommendation A). It is unclear if the significant improvements seen after 3–5 weeks of oral administration at a dosage of >600 mg/day are clinically relevant. |
format | Online Article Text |
id | pubmed-3272801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32728012012-02-13 Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials Mijnhout, Gerritje S. Kollen, Boudewijn J. Alkhalaf, Alaa Kleefstra, Nanno Bilo, Henk J. G. Int J Endocrinol Review Article Objective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid”, “thioctic acid”, “diabet(∗)”, and the MeSH-terms “thioctic acid” and “diabetes mellitus”. Randomised controlled trials using the TSS score as the outcome measure were selected and assessed for their methodological quality. Study selection and quality assessment were performed independently by three observers. Results. Overall, the pooled standardized mean difference estimated from all trials revealed a reduction in TSS scores of −2.26 (CI: −3.12 to −1.41; P = 0.00001) in favour of alpha lipoic acid administration. Subgroup analyses of oral administration (−1.78 CI: −2.45 to −1.10; P = 0.00001) and intravenous administration (−2.81 CI: −4.16 to −1.46; P = 0.0001) confirmed the robustness of the overall result. Conclusions. When given intravenously at a dosage of 600 mg/day over a period of 3 weeks, alpha lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain (grade of recommendation A). It is unclear if the significant improvements seen after 3–5 weeks of oral administration at a dosage of >600 mg/day are clinically relevant. Hindawi Publishing Corporation 2012 2012-01-26 /pmc/articles/PMC3272801/ /pubmed/22331979 http://dx.doi.org/10.1155/2012/456279 Text en Copyright © 2012 Gerritje S. Mijnhout et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Mijnhout, Gerritje S. Kollen, Boudewijn J. Alkhalaf, Alaa Kleefstra, Nanno Bilo, Henk J. G. Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
title | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
title_full | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
title_fullStr | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
title_short | Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials |
title_sort | alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272801/ https://www.ncbi.nlm.nih.gov/pubmed/22331979 http://dx.doi.org/10.1155/2012/456279 |
work_keys_str_mv | AT mijnhoutgerritjes alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials AT kollenboudewijnj alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials AT alkhalafalaa alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials AT kleefstrananno alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials AT bilohenkjg alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials |